The results reveal that SYTZD might reduce liver inflammation and injury by causing a decrease in the relative protein levels of HIF-1α and VEGFA for alleviating NAFLD. The gene discussed is HIF1A; the disease is metabolic dysfunction-associated steatotic liver disease.